{"product_id":"inm-pestle-analysis","title":"(INM) InMed Pharmaceuticals Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePlan Smarter. Present Sharper. Compete Stronger.\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis InMed Pharmaceuticals Inc. PESTLE Analysis explains the political, economic, social, technological, legal, and environmental forces shaping the company and why they matter for strategy, investment, or research; the page shows a real preview\/sample of the report so you can judge style and depth before buying—purchase the full version to get the complete ready-to-use analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCanadian biotech oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc., based in Vancouver, is directly exposed to Health Canada, which oversees clinical trials, GMP manufacturing, and cannabinoid handling under federal rules. Canada’s 10 provinces and 3 territories can also affect site permits and lab work, so policy consistency matters for timelines. Stable alignment can speed development, while policy shifts can slow approvals and supply flow.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCannabinoid policy environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. works in cannabinoid-derived therapies, so it still faces policy risk from cannabis laws and public-sector scrutiny, even when the product is pharmaceutical. In the U.S., only a small set of cannabinoid medicines have clear regulatory paths, while marijuana remains federally controlled as Schedule I, which can slow trials and investor appetite. Clearer government treatment of cannabinoid medicines would lower approval risk and help support funding and execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCross-border regulatory coordination\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc.'s therapies face approvals in both the U.S. and Canada, so one program can be judged by two sets of rules. The FDA and Health Canada can differ on clinical evidence, labeling, and GMP standards, which raises cost and timing risk. The FDA had 55 novel drug approvals in 2024, showing how selective the path is, while cross-border alignment would make future launch planning easier.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic health and rare disease priority\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eINM-755 targets epidermolysis bullosa, one of more than 7,000 rare diseases, so it fits a high-priority public health area that can draw policy attention. Rare-disease drugs can qualify for orphan incentives, including 7 years of U.S. market exclusivity and FDA priority review, which can speed development for a clinical-stage Company like InMed Pharmaceuticals Inc. The focus can also raise visibility with regulators and payers when treatment options are scarce.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRare disease = policy focus\u003c\/li\u003e\n\u003cli\u003eOrphan drugs get U.S. incentives\u003c\/li\u003e\n\u003cli\u003ePriority review can speed timelines\u003c\/li\u003e\n\u003cli\u003eVisibility matters for clinical-stage firms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eResearch funding climate\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiopharmaceutical work still leans on public and private capital, and that matters for InMed Pharmaceuticals Inc. In Canada, the SR\u0026amp;ED program can refund up to 35% of eligible R\u0026amp;D for CCPCs, while non-CCPCs can claim 15%; those credits can help pay for IND-enabling studies and early clinical work.\u003c\/p\u003e\n\u003cp\u003eSupportive grants and tax credits matter because cannabinoid drug development is slow and expensive. Global biotech VC funding was about $21.0 billion in Q1 2025, up from $13.6 billion in Q4 2024, showing how tighter capital still shapes pipeline timing and spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTax credits lower R\u0026amp;D cash burn\u003c\/li\u003e\n\u003cli\u003eGrants can fund preclinical work\u003c\/li\u003e\n\u003cli\u003eCapital access affects trial speed\u003c\/li\u003e\n\u003cli\u003eWeak funding can delay IND progress\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInMed Faces Dual-Regulator Risk as FDA Bar Stays High\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. faces policy risk from Canada’s federal Health Canada rules and U.S. FDA drug review, so approval timing depends on two regulators. The FDA approved 50 novel drugs in 2025, showing the bar stays high. Rare-disease status can help, but rules still drive cost and speed.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA novel approvals\u003c\/td\u003e\n\u003ctd\u003e50 in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOrphan incentive\u003c\/td\u003e\n\u003ctd\u003e7 years U.S. exclusivity\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCanada R\u0026amp;D credit\u003c\/td\u003e\n\u003ctd\u003eUp to 35% for CCPCs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps how Political, Economic, Social, Technological, Environmental, and Legal forces shape InMed Pharmaceuticals Inc.’s risks and opportunities.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise InMed Pharmaceuticals PESTLE snapshot that quickly highlights key external risks and opportunities for easier planning and decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eCites primary industry reports, clinical trial registries, SEC filings, and peer-reviewed studies to make InMed’s assumptions verifiable and due-diligence ready.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage revenue gap\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. remains clinical-stage, so revenue is still tied to financing, not product sales. The Company reported no commercial product revenue in its latest filings, while R and D continued to drive cash use, leaving liquidity and market access as key risks. For development-stage biotech, this gap means every trial delay can quickly tighten the cash runway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R and D intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. is funding Phase I, preclinical, and IND-enabling work across several programs, and each step adds toxicology, pharmacology, formulation, and trial-ops spend. For small biotech firms, R\u0026amp;D burn often runs in the millions per quarter, so rising research costs can quickly squeeze runway. That pressure can force InMed Pharmaceuticals Inc. to rank programs, slow timelines, or cut weaker candidates.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancing dependence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals relies on equity raises, partnerships, and grants, like most small biotech firms. In 2025, small-cap life sciences stayed tightly funded as risk appetite swung fast, so share issues can get expensive. InMed has to keep investors interested to back its pipeline and biosynthesis platform.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCurrency exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. is Canadian, but its therapies and contracts can span Canada and the U.S., so cash flows may swing between Canadian dollars and U.S. dollars. In 2025, the CAD often traded near US$0.70, so even small FX moves can change reported R\u0026amp;D spend, supplier bills, and future sales values.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMulti-currency costs and sales\u003c\/li\u003e\n\u003cli\u003eCAD\/USD volatility can distort margins\u003c\/li\u003e\n\u003cli\u003eFX swings affect cash planning\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCommercial opportunity in specialty therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eINM-755, INM-088, and INM-405 aim at dermatology, ocular disease, and pain, three large markets. Dermatology drugs are a roughly $50 billion global category, while eye-disease treatments and pain drugs each run into the tens of billions, so even a small share can be meaningful for InMed Pharmaceuticals Inc. if clinical data stay strong.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall share can still move revenue.\u003c\/li\u003e\n\u003cli\u003ePricing drives upside.\u003c\/li\u003e\n\u003cli\u003eReimbursement can cap adoption.\u003c\/li\u003e\n\u003cli\u003ePartner terms shape economics.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe real economic value will depend on payor coverage, launch price, and any licensing or co-development deal. For a small biotech, positive phase data can change valuation fast because one approved niche product in a multi-billion-dollar category can outweigh years of R\u0026amp;D spend.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInMed’s Cash Burn and FX Risk Keep Near-Term Pressure High\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. faces weak near-term economics because it is still clinical-stage, so cash use depends on financing, not sales. Its 2025 spend stays tied to R\u0026amp;D across Phase I and preclinical work, which keeps runway pressure high. Funding risk is sharper in small-cap biotech when equity markets tighten. CAD\/USD swings also affect reported costs and future sales.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct\" green_head blur_tbl\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eImplication\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 CAD\/USD near 0.70\u003c\/td\u003e\n\u003ctd\u003eFX can move costs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNo product revenue\u003c\/td\u003e\n\u003ctd\u003eFinancing risk stays high\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D-led cash use\u003c\/td\u003e\n\u003ctd\u003eRunway stays tight\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eInMed Pharmaceuticals Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact InMed Pharmaceuticals Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003cp\u003eNo placeholders or teasers: the content, layout, and insights visible in this preview are the final downloadable file you’ll own immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRare disease patient need\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEpidermolysis bullosa affects about 1 in 50,000 births, and the DEBRA network estimates 500,000 people live with it worldwide. Families often seek therapies that can cut pain, skin blistering, and wound care time, so unmet need is high. That pressure can strengthen patient advocacy and support clinical development for InMed Pharmaceuticals Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDemand for non-opioid pain options\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINM-405 fits a clear social shift toward non-opioid pain care. The CDC reported about 81,083 opioid-involved overdose deaths in the U.S. in 2023, while about 51.6 million adults lived with chronic pain, so patients and clinicians keep looking for safer options. That supports interest in cannabinoid-based analgesic research with lower dependency risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStigma around cannabis-derived medicines\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStigma still weighs on InMed Pharmaceuticals Inc. because public views on cannabis can color how cannabinoid drugs are judged, even when they are standardized medicines. In the U.S., only 4 cannabinoid or cannabis-derived drugs have FDA approval, which shows how narrow the path to acceptance remains. Strong clinical data is key to move patients and prescribers from caution to trust.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAgeing and chronic disease burden\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAgeing raises the load of ocular and skin disease: WHO says 1 in 6 people will be 60+ by 2030, and 2.1 billion will be 60+ by 2050. That shift lifts demand for glaucoma and chronic dermatology therapies, both of which need long-term treatment.\u003c\/p\u003e\n\u003cp\u003eGlaucoma already affects about 76 million people worldwide, and cases are expected to rise as populations age. Chronic skin disorders also recur over time, so therapies with steady efficacy can support repeat use and persistent demand.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eAgeing expands eye and skin disease cases.\u003c\/li\u003e\n\u003cli\u003eGlaucoma needs ongoing, recurring care.\u003c\/li\u003e\n\u003cli\u003eChronic dermatology supports repeat therapy demand.\u003c\/li\u003e\n\u003cli\u003eInMed aligns with this demographic need.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePatient trust in evidence-based medicine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a clinical-stage Company, InMed Pharmaceuticals Inc. must turn lab results into randomized, reproducible human data to win patient and physician trust. That matters because social acceptance now tracks evidence, not promise, so peer-reviewed trial results and clear endpoints shape adoption. One clean rule: no strong data, no broad trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRandomized data drives acceptance.\u003c\/li\u003e\n\u003cli\u003ePeer review lowers skepticism.\u003c\/li\u003e\n\u003cli\u003eClear trial design builds trust.\u003c\/li\u003e\n\u003cli\u003eClinical proof beats early promise.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRising Demand for Non-Opioid Pain Relief and EB Care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. benefits from strong unmet need: EB affects about 1 in 50,000 births, and about 500,000 people live with it worldwide. That keeps patient advocacy and demand for better skin care high.\u003c\/p\u003e\n\u003cp\u003eSocial pull for non-opioid pain care is also real, with 51.6 million U.S. adults living with chronic pain in 2023 and 81,083 opioid-involved deaths. Trust still depends on clear clinical proof.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEB prevalence\u003c\/td\u003e\n\u003ctd\u003e1 in 50,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal EB patients\u003c\/td\u003e\n\u003ctd\u003e500,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. chronic pain\u003c\/td\u003e\n\u003ctd\u003e51.6M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpioid deaths\u003c\/td\u003e\n\u003ctd\u003e81,083\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINM-755 Phase I development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINM-755, InMed Pharmaceuticals Inc.'s cannabinol-infused topical cream, is in Phase I testing for epidermolysis bullosa, a rare disease affecting about 1 in 50,000 births. The key technical risks are formulation stability, dose consistency, and clean safety readouts in first-in-human use. If early data stay positive, later-stage development should be less risky and more credible.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntegraSyn biosynthesis platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntegraSyn is InMed Pharmaceuticals Inc.’s biosynthesis platform for making pharmaceutical-grade cannabinoids with tighter control than plant-derived extraction. \u003c\/p\u003e\n\u003cp\u003eIf it scales as planned, biosynthesis can reduce batch-to-batch variability and support steadier supply, which matters for regulated drug development. \u003c\/p\u003e\n\u003cp\u003eThat could lower reliance on crop cycles and strengthen InMed Pharmaceuticals Inc.’s manufacturing flexibility, but only if yields, purity, and cost stay stable at scale. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePreclinical pipeline breadth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. is advancing at least two preclinical programs, INM-088 for glaucoma and INM-405 for pain relief, so its pipeline is broader than a single-asset story. Running multiple programs needs shared discovery, screening, and translational tools, which can improve speed and lower per-program cost. That breadth also gives optionality if one asset moves faster or shows stronger data first.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eIND-enabling research capability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. is doing IND-enabling pharmacology and preclinical toxicology work, the last major step before human testing can expand. In the U.S., an IND can face a 30-day FDA review window, so clean data matters. Strong GLP toxicology and dose-ranging results cut the risk of a clinical hold, delay, or extra studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePreclinical data supports IND filings.\u003c\/li\u003e\n\u003cli\u003e30-day FDA review is a key gate.\u003c\/li\u003e\n\u003cli\u003eBetter data lowers hold risk.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBayMedica collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc.'s work with BayMedica helps speed cannabinoid R\u0026amp;D by splitting lab, formulation, and process know-how across teams. BayMedica was acquired by InMed in 2021, so the tech gain is now internal: stronger control over candidate selection, manufacturing routes, and scale-up choices.\u003c\/p\u003e\n\u003cp\u003eThat matters because InMed is still a small-cap biotech, so each failed candidate can strain cash and time. Shared expertise lowers technical risk and can cut development delays before the next clinical or production step.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFaster formulation screening\u003c\/li\u003e\n\u003cli\u003eBetter process selection\u003c\/li\u003e\n\u003cli\u003eLower scale-up risk\u003c\/li\u003e\n\u003cli\u003eMore efficient R\u0026amp;D use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInMed’s cannabinoid edge meets a critical Phase I execution test\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc.’s main tech edge is its cannabinoid biosynthesis and topical R\u0026amp;D, but execution still hinges on clean scale-up, stable purity, and first-in-human safety. INM-755 is in Phase I for a disease seen in about 1 in 50,000 births, and the FDA’s IND review can take 30 days, so data quality is the key gate.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eINM-755\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEB incidence\u003c\/td\u003e\n\u003ctd\u003e~1 in 50,000 births\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND review\u003c\/td\u003e\n\u003ctd\u003e30 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical trial compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals’ human studies depend on ethics and regulatory approvals, and in the U.S. an IND can face a 30-day FDA review before Phase I starts. Phase I must follow the written protocol, safety checks, and adverse-event reporting, or the trial can be paused. Non-compliance can delay data readout and trigger FDA action, including clinical holds.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eControlled substance framework\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eCannabinoid research sits under controlled-substance rules in many markets, so InMed Pharmaceuticals Inc. must secure special licenses, locked storage, and full chain-of-custody records. Even pharma-grade inputs can trigger audit checks and import\/export delays, which lifts compliance cost and slows R\u0026amp;D. That legal load also raises the risk of inspection findings and permit loss.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFor InMed Pharmaceuticals Inc., patent protection is the main moat: filings around formulations, synthesis, and therapeutic use can lock in exclusivity and strengthen licensing talks. InMed’s FY2025 filing still reflected a development-stage business with no meaningful commercial scale, so IP matters more than sales today. Weak patents would quickly reduce deal value and future commercialization upside.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eProduct liability exposure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc.'s topical, ocular, and pain therapies each carry strict safety and efficacy duties, so any adverse event in a trial or post-launch can trigger claims, recalls, or regulator reviews. That risk is highest in small biotech, where one serious signal can delay a program and raise legal costs fast.\u003c\/p\u003e\n\u003cp\u003eFor InMed Pharmaceuticals Inc., strong adverse-event tracking, source-data files, and protocol compliance are key defenses. Clear documentation matters across every study phase, because liability often turns on what the company knew, when it knew it, and how it responded.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSafety issues can trigger lawsuits.\u003c\/li\u003e\n\u003cli\u003eRegulators may demand extra data.\u003c\/li\u003e\n\u003cli\u003eDocumentation reduces legal exposure.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eData and labeling requirements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. must keep every drug claim tied to accepted clinical evidence and approved labeling, or risk misbranding under FDA rules. For cannabinoid medicines, wording has to stay tight: no off-label promises, no unsupported efficacy claims, and no disease claims beyond the label.\u003c\/p\u003e\n\u003cp\u003eThat matters because one bad claim can trigger warning letters, product pulls, or costly remediation, and it can also damage trust with regulators and physicians.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse only label-backed claims\u003c\/li\u003e\n\u003cli\u003eKeep cannabinoid wording precise\u003c\/li\u003e\n\u003cli\u003eAvoid off-label promotion\u003c\/li\u003e\n\u003cli\u003eLimit enforcement and reputational risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInMed’s Legal Risk Hinges on FDA Trials, Compliance, and Patent Protection\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. faces tight legal control on trials, cannabis handling, and drug promotion. INDs can face a 30-day FDA review, and any protocol or safety lapse can trigger a clinical hold. Patent strength is still key, because as a FY2025 development-stage company with no meaningful sales, IP and compliant claims protect future value.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal risk\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eIND review\u003c\/td\u003e\n\u003ctd\u003e30 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial scale\u003c\/td\u003e\n\u003ctd\u003eNone in FY2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBio-based cannabinoid production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIntegraSyn’s biosynthesis route can make cannabinoids without large-scale crop farming, so InMed Pharmaceuticals Inc. can cut reliance on farmland and weather swings. This matters as indoor cannabis cultivation can use up to 20 times more energy than open-field growing, lifting emissions and costs. A controlled process also supports steadier raw-material output and tighter batch consistency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory waste management\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003ePharmaceutical research at Company Name generates chemical waste, solvents, and single-use plastics, and WHO says about 15% of healthcare waste is hazardous. For InMed Pharmaceuticals Inc., tight segregation, treatment, and recycling systems cut disposal costs and help avoid compliance penalties. Lab waste controls also matter for ESG scoring, where environmental performance is now a standard investor check.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnergy use in R and D\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc.'s R and D sites likely face high power demand, since labs can use 5 to 10 times more energy than office space, mainly for refrigeration, analytical systems, and controlled rooms. Efficient HVAC, freezers, and lighting can cut costs and lower emissions. As the pipeline grows, energy management becomes a bigger operating risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply chain sustainability\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. relies on specialized reagents, sterile packaging, and cold-chain logistics, so supplier screening matters. Sustainable sourcing can cut risk and help meet partner ESG demands, while transport or input delays can push back development timelines. In biotech, even one missed lot can slow a study or batch release.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse vetted, lower-risk suppliers.\u003c\/li\u003e\n\u003cli\u003eTrack transport and input delays.\u003c\/li\u003e\n\u003cli\u003ePrioritize recyclable, compliant packaging.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eClimate resilience in operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc., based in Vancouver, needs climate-resilient operations because heavy rain, snow, and transport disruption can delay samples, trial materials, and lab supplies. Canada’s 2024 average temperature was 2.6°C above the 1961-1990 baseline, which reinforces the need for stronger continuity plans. Climate-aware logistics help protect sample integrity and keep research timelines on track.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eWeather can delay shipments.\u003c\/li\u003e\n\u003cli\u003eBackup storage protects samples.\u003c\/li\u003e\n\u003cli\u003eContinuity plans protect trials.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInMed’s Biosynthesis Cuts Farm Risk, But Labs Face Energy and Climate Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eInMed Pharmaceuticals Inc. benefits from Biosynthesis because it avoids crop farming, cutting exposure to weather and land use swings. Lab and R and D sites still face high energy and waste loads; healthcare waste is about 15% hazardous, and labs can use 5 to 10 times more power than offices. Climate disruption can delay samples and inputs, so backup logistics matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eData point\u003c\/th\u003e\n\u003cth\u003eImpact\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnergy\u003c\/td\u003e\n\u003ctd\u003e5 to 10x office use\u003c\/td\u003e\n\u003ctd\u003eHigher cost\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWaste\u003c\/td\u003e\n\u003ctd\u003e15% hazardous\u003c\/td\u003e\n\u003ctd\u003eCompliance risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClimate\u003c\/td\u003e\n\u003ctd\u003e2024 Canada +2.6°C\u003c\/td\u003e\n\u003ctd\u003eDelay risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234491670793,"sku":"inm-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/inm-pestle-analysis.webp?v=1785722014","url":"https:\/\/dcfanalyst.com\/products\/inm-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}